9-Me-BC: Dopamine Repair & Neuroprotection
Last updated: April 2026 — All data from animal & in vitro models only
9-Methyl-β-carboline upregulates tyrosine hydroxylase, BDNF, GDNF, and 8+ neurotrophic factors in preclinical models. Favored by biohackers for dopamine restoration after stimulant tolerance. No human clinical trials exist. MAO inhibitor. Commonly handled as light-sensitive (no published stability data).
🧪 Buy 9-Me-BC at Swiss Chems →Upregulated (Preclinical)
Never Established
Store in Amber Container
What Is 9-Me-BC?
Not a peptide — but 100% in our audience's wheelhouse. A synthetic β-carboline alkaloid with a surprising profile: neuroprotective where most β-carbolines are neurotoxic.
β-Carbolines are a class of pyridoindole compounds found in plants, cooked foods, and even synthesized endogenously from tryptophan. β-Carbolines have predominantly been identified as neurotoxic (Hamann et al., 2008), and some are structurally similar to MPTP, the compound that destroys dopaminergic neurons in Parkinson's research. 9-Me-BC is an exception: it was neuroprotective rather than toxic in primary dopaminergic cultures (Polanski et al., 2010), and in one rat study it was given after an MPP+ lesion and was associated with restoration of dopaminergic markers (Wernicke et al., 2010).
Tyrosine hydroxylase is the rate-limiting enzyme that converts L-tyrosine → L-DOPA → Dopamine. In rodent primary dopaminergic cultures, 9-Me-BC at 70µM increased TH+ neuron count by 27 ± 7%. This effect was independent of dopamine receptor stimulation — it's doing more than blocking reuptake or forcing release. It upregulates the machinery for dopamine production itself. (Keller et al. 2020, PMC8592951)
Monoamine oxidase (MAO) breaks down dopamine, serotonin, and norepinephrine. 9-Me-BC inhibits both isoforms: MAO-A with an IC₅₀ of 1 µM (potent) and MAO-B at IC₅₀ of 15.5 µM. The authors suggest this dual MAO inhibition might contribute to the increased dopamine content seen in cell culture (Keller et al. 2020); MAO-B inhibition is also how selegiline and rasagiline, drugs used in Parkinson's treatment, work. Implication: potential drug interactions with serotonergics and tyramine-rich foods.
9-Me-BC's neurostimulatory effects are mediated through the PI3K/Akt pathway (Keller et al., 2020), as well as interaction with tyrosine kinases: PKA, PKC, EGF receptor, FGF receptor, and NCAM (Polanski et al., 2010). This broad kinase interaction profile explains the many downstream neurotrophic effects. It also means the compound touches many critical cellular signaling cascades, so off-target effects are plausible.
Neurotrophic Factor Upregulation Profile
This is what makes 9-Me-BC stand out in the biohacker community. The compound does more than boost dopamine: it upregulates the survival and growth signals for dopaminergic neurons themselves. Data from astrocyte cultures (Keller et al. 2020; PMC8592951) and one in vivo rat study that reports BDNF, CDNF, cerebellin-1 and CNTF induction (Wernicke et al. 2010).
⚠️ All data from astrocyte cell cultures and rodent studies. Translation to human CNS is not established.
How It Compares to Stimulants
Community interest in 9-Me-BC centres on claims that it differs from stimulants; none of the cited studies compares them head-to-head. Here's how its preclinical profile lines up against common dopamine-affecting compounds.
Cross-compound comparison is approximate. All three have different risk profiles and evidence bases. Not a recommendation to use any of these compounds.
What the Animal Research Shows
All data from in vitro cell studies and rodent models. Hamann et al. 2008 (Neurochem Int), Polanski et al. 2010 (J Neurochem), Keller et al. 2020 (J Neural Transm), and one in vivo rat study, Wernicke et al. 2010 (Pharmacol Rep). No completed human trials as of 2026.
Risks & Critical Warnings
9-Me-BC is a research chemical with no human safety data. There are several specific, non-obvious risks that every person researching this compound should understand.
9-Me-BC is reported to degrade on UV/light exposure (community handling guidance; no published stability study is cited here) — breakdown could leave it inactive or produce unknown degradation byproducts. The usual advice: store in opaque amber glass containers, refrigerate, minimize light exposure during dosing. Some community anecdotes also suggest avoiding bright sun or UV exposure during active use cycles; no cited source studies light sensitivity in users.
9-Me-BC inhibits both MAO-A and MAO-B. This creates potential interactions with:
• Serotonergic compounds (SSRIs, SNRIs, SARMs that affect serotonin, tryptophan) — risk of serotonin syndrome
• Tyramine-rich foods (aged cheeses, cured meats, fermented foods) — risk of hypertensive crisis
• Stimulants (amphetamines, MDMA) — severely amplified and potentially dangerous effects
• Other dopaminergics (pramipexole, L-DOPA) — unpredictable amplification
These are the same interaction rules as pharmaceutical MAO inhibitors like phenelzine.
Dosing & Handling
The following are community-reported protocols. These are not medically validated doses. No pharmacokinetic or safety studies have established safe human dosing ranges. These are what researchers self-report — use at your own risk with full understanding of the unknowns.
- Dose: no human dose has been established — none of the cited studies tests a human dose or route
- Route (community-reported): sublingual (under the tongue)
- Frequency (community-reported): once daily, typically morning
- Cycling (community-reported): users describe on/off cycles; none of the cited studies tests cycling
- Form: typically sourced as powder or capsules
- Some users report: Nasal administration (insufflation) but this has additional unknown risks
- Store in amber glass vials or opaque containers — commonly preferred over clear plastic/glass
- Some users refrigerate it when not in use
- Minimize light exposure during weighing and dosing
- Work in dim lighting or under red/amber light when handling
- During cycles: some users reduce sun exposure and avoid tanning beds (anecdotal)
- SSRIs / SNRIs / any serotonin-affecting medications
- Tryptophan or 5-HTP supplements
- Stimulants: amphetamines, MDMA, high-dose caffeine
- Other dopaminergics: pramipexole, L-DOPA, bromantane
- Large quantities of aged cheeses, cured meats, or fermented foods (tyramine)
- Opioids (some have serotonergic activity)
Evidence Level — Be Honest
9-Me-BC sits at the frontier of the in vitro-to-human translation gap. The mechanisms are compelling and well-characterized in cell culture, with one in vivo rat study. But the leap to humans is large and unproven.
Two collaborating groups (TU Dresden and Charité Berlin) have reported neurostimulative and neuroprotective findings in rodent primary cultures (Hamann 2008, Polanski 2010, Keller 2020) and in one in vivo rat model (Wernicke 2010). Independent replication outside these groups is not cited here. The proposed mechanisms — TH upregulation, neurotrophic factor stimulation, MAO inhibition — have been studied at the cellular level, though the authors themselves describe parts of the mechanism as only partly explained. This is not zero-evidence speculation.
Cell culture results often fail to translate to whole animals, and animal results often fail to translate to humans. Many compounds that regenerate dopaminergic neurons in Parkinson's animal models (including GDNF infusion trials) have failed to demonstrate equivalent human benefit. Preclinical data is a starting point, not a result.
As of 2026, no Phase I safety study, no human pharmacokinetic data, no dose-finding trial, and no RCT exists for 9-Me-BC. The community self-experimentation is working in the dark. Effective dose, toxic dose, bioavailability, half-life, and long-term safety in humans are all unknown.
The Journal of Neural Transmission study (Keller et al., 2020) explicitly concluded: "9-me-BC have a plethora of beneficial effects on dopaminergic neurons warranting its exploration as a new multimodal anti-parkinsonian medication." A compound targeting TH, BDNF, GDNF, and α-synuclein simultaneously with a single small molecule is scientifically interesting. Whether it survives human trials is genuinely unknown.
Key Takeaways
- Upregulates tyrosine hydroxylase (dopamine synthesis enzyme) in rodent neurons
- Stimulates 8+ neurotrophic factors including BDNF, GDNF, Artemin, and NT-3
- Inhibits MAO-A (IC₅₀ 1µM) and MAO-B (IC₅₀ 15.5µM) — may contribute to higher dopamine content in culture
- Restored TH+ neuron counts and striatal dopamine in rats after an MPP+ toxin lesion (one in vivo study, Wernicke 2010)
- Reduces α-synuclein protein and microglia-driven inflammation in cell culture
- Cited studies report TH and neurotrophic-factor upregulation and MAO inhibition; none compares it with stimulants, and its dopamine-content increase in culture was slight and non-significant (Hamann 2008)
- Commonly handled as light-sensitive (no published stability data cited)
- Human bioavailability, pharmacokinetics, and half-life are entirely unknown
- Whether in vitro / animal neurotrophic effects translate to humans at all
- Safe human dose range — no Phase I data exists
- Long-term effects of MAO inhibition via 9-Me-BC in chronic use
- Whether "stimulant tolerance reversal" community claims hold up in any controlled setting
- Optimal storage conditions, stability timeline, and degradation product safety
- Interaction profile with the full range of common supplements and medications
Primary Sources
🛒 Recommended Products
Supplies for light-protected storage and precise measurement, in line with common handling practice for 9-Me-BC.
Affiliate links — support HighPeptides at no extra cost.
Related Research
47-page guide: protocols, dosing, sourcing — everything in one place.
Get the guide — $19 (normally $29) → New to peptides? Start with the $19 Buyer’s Playbook → All ebooks & guides →This page is for educational and informational purposes only. 9-Me-BC is a research chemical with no completed human clinical trials as of 2026. All efficacy and mechanistic data comes from in vitro cell studies and rodent models — these findings may not translate to humans. 9-Me-BC is a monoamine oxidase inhibitor with significant potential drug interactions. Do not use this or any research chemical without consulting a qualified physician. HighPeptides does not sell 9-Me-BC; vendor and product links on this page are affiliate links, and we may earn a commission if you buy through them. This is not medical advice.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars — metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.